<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02088398</url>
  </required_header>
  <id_info>
    <org_study_id>ACE-HV-100</org_study_id>
    <nct_id>NCT02088398</nct_id>
  </id_info>
  <brief_title>Alternative 10 mg/mL Liquid Formulation of ACY 1215 (Ricolinostat) in Healthy Subjects</brief_title>
  <official_title>Open-Label, Randomized, Single Dose, 3-Period Crossover to Evaluate the Relative Bioavailability and Food-Effect on Pharmacokinetics of Alternative 10 mg/mL Liquid Formulation ACY-1215 (Ricolinostat) in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acetylon Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acetylon Pharmaceuticals Incorporated</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be an open-label, randomized, single dose, 3-period crossover PK study. This&#xD;
      study will comprise 3 treatment periods with a 4-day washout between periods. On Day -1,&#xD;
      subjects will be randomized to 1 of 6 treatment sequences. On Days 1, 5, and 9, subjects will&#xD;
      be administered Treatment A, B, or C according to the randomization schedule.&#xD;
&#xD;
        -  Treatment A: a single dose of 160 mg ACY-1215 CLF (20 mg/mL) in the fed state&#xD;
&#xD;
        -  Treatment B: a single dose of 120 mg ACY-1215 ALF (10 mg/mL) in the fed state&#xD;
&#xD;
        -  Treatment C: a single dose of 120 mg ACY-1215 ALF (10 mg/mL) in the fasted state&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be confined to the Clinical Research Unit (CRU) from the time of Check-in (Day&#xD;
      -1) to Day 10. Predose blood and urine samples will be obtained prior to each ACY-1215&#xD;
      administration. Following administration of ACY-1215 in each period, blood and urine samples&#xD;
      will be collected at specified timepoints or intervals through 24 hours postdose for the&#xD;
      determination of the PK of a single oral dose of ACY-1215. Subjects will be discharged from&#xD;
      the CRU on Day 10, following the completion of the last PK collection and successful&#xD;
      completion and evaluation of discharge safety tests. Subjects will return to the clinic for a&#xD;
      Follow-up visit 5 to 7 days after the last dose of ACY-1215 (Days 14 to 16) for additional&#xD;
      safety evaluations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve From Zero to Last Time - AUC0-last</measure>
    <time_frame>0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12 and 24 hr post first dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability parameters</measure>
    <time_frame>Day 1 (first dose of ACY-1215) to Day 16</time_frame>
    <description>Changes from baseline in clinical laboratory assessments, vital signs, electrocardiogram values, and physical exam. This includes collection of adverse events and the collection of concomitant medications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Extrapolated Infinite Time</measure>
    <time_frame>0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12 and 24 hr post first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12 and 24 hr post first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Decay Half-Life</measure>
    <time_frame>0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12 and 24 hr post first dose</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>160 mg ACY-1215 CLF (20 mg/mL) fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>• Treatment A: a single dose of 160 mg ACY-1215 CLF (20 mg/mL) in the fed state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>120 mg ACY-1215 ALF (10 mg/mL) fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>• Treatment B: a single dose of 120 mg ACY-1215 ALF (10 mg/mL) in the fed state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>120 mg ACY-1215 ALF (10 mg/mL) fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>• Treatment C: a single dose of 120 mg ACY-1215 ALF (10 mg/mL)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACY-1215</intervention_name>
    <arm_group_label>120 mg ACY-1215 ALF (10 mg/mL) fasted</arm_group_label>
    <arm_group_label>120 mg ACY-1215 ALF (10 mg/mL) fed</arm_group_label>
    <arm_group_label>160 mg ACY-1215 CLF (20 mg/mL) fed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 to 65 years of age, inclusive&#xD;
&#xD;
          -  BMI range 18.5 to 32.0 kg/m2&#xD;
&#xD;
          -  in good health, as determined by no clinically significant findings from medical&#xD;
             history, 12-lead ECG, vital signs&#xD;
&#xD;
          -  clinical laboratory evaluations, CBC, coagulation, and UA&#xD;
&#xD;
          -  negative test for selected drugs of abuse&#xD;
&#xD;
          -  negative hepatitis panel and negative HIV antibody&#xD;
&#xD;
          -  females of non-childbearing potential as outlined in protocol&#xD;
&#xD;
          -  males either be sterile or agree to use contraception as outlined in protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  significant history or clinical manifestation of any metabolic, allergic,&#xD;
             dermatological, hepatic, renal, hematological, pulmonary, cardiovascular,&#xD;
             gastrointestinal, neurological, or psychiatric disorder&#xD;
&#xD;
          -  history of significant hypersensitivity, intolerance, or allergy to any drug compound,&#xD;
             food, or other substance&#xD;
&#xD;
          -  history of stomach or intestinal surgery or resection that would potentially alter&#xD;
             absorption and/or excretion of orally administered drugs&#xD;
&#xD;
          -  history of Gilbert's Syndrome or suspicion of Gilbert's Syndrome&#xD;
&#xD;
          -  abnormality in the 12-lead ECG (e.g. QTcF of &gt;450 msec, a history of a prolonged&#xD;
             QTc-interval or Brugada syndrome)&#xD;
&#xD;
          -  history of alcoholism or drug addiction within 1 year prior&#xD;
&#xD;
          -  participation in any other investigational study drug trial in which receipt of an&#xD;
             investigational study drug as outlined in protocol&#xD;
&#xD;
          -  use of any prescription medications/products within 14 days (30 days for cytochrome&#xD;
             P450 [CYP]-inducing or inhibiting products as outlined in protocol)&#xD;
&#xD;
          -  use of any over-the-counter, nonprescription preparations within 14 days&#xD;
&#xD;
          -  use of any tobacco or nicotine-containing products within 6 months and during study;&#xD;
&#xD;
          -  poor peripheral venous access&#xD;
&#xD;
          -  donation of blood from 30 days prior to Screening through the Follow-up visit&#xD;
&#xD;
          -  any acute or chronic condition that, in the opinion of the Investigator, would limit&#xD;
             the subject's ability to complete and/or participate in this clinical study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas Siebers, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit Incorporated</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <study_first_submitted>March 5, 2014</study_first_submitted>
  <study_first_submitted_qc>March 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2014</study_first_posted>
  <last_update_submitted>September 10, 2014</last_update_submitted>
  <last_update_submitted_qc>September 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>relative bioavailability</keyword>
  <keyword>food-effect</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ricolinostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

